Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sander J Robins

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Archives of Internal Medicine|February 13, 2002
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention TrialJohn A Nyman, Melissa S Martinson, David Nelson, et al.
Circulation|December 29, 2005
Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart StudySekar Kathiresan, James D Otvos, Lisa M Sullivan, et al.
The American Journal of Cardiology|October 23, 2008
Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study)Nisha I Parikh, Shih-Jen Hwang, Qiong Yang, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 16, 2002
Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention TrialMargaret E Brousseau, John J O'Connor, Jose M Ordovas, et al.
Journal of Lipid Research|August 5, 2004
Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention TrialMargaret E Brousseau, Allison L Goldkamp, Dorothea Collins, et al.
The Journal of Clinical Endocrinology and Metabolism|May 21, 2010
Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart studySarah Rosner Preis, Joseph M Massaro, Udo Hoffmann, et al.
Archives of Neurology|November 15, 2006
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart StudyErnst J Schaefer, Vanina Bongard, Alexa S Beiser, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 11, 2006
Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart StudyDouglas S Lee, Jane C Evans, Sander J Robins, et al.
Vascular Medicine (London, England)|December 19, 2014
The relation of red blood cell fatty acids with vascular stiffness, cardiac structure and left ventricular function: the Framingham Heart StudyBernhard M Kaess, William S Harris, Sean Lacey, et al.
Obesity (Silver Spring, Md.)|March 27, 2010
Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart studySarah R Preis, Joseph M Massaro, Sander J Robins, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Archives of Internal Medicine|February 13, 2002
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention TrialJohn A Nyman, Melissa S Martinson, David Nelson, et al.
Circulation|December 29, 2005
Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart StudySekar Kathiresan, James D Otvos, Lisa M Sullivan, et al.
The American Journal of Cardiology|October 23, 2008
Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study)Nisha I Parikh, Shih-Jen Hwang, Qiong Yang, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 16, 2002
Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention TrialMargaret E Brousseau, John J O'Connor, Jose M Ordovas, et al.
Journal of Lipid Research|August 5, 2004
Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention TrialMargaret E Brousseau, Allison L Goldkamp, Dorothea Collins, et al.
The Journal of Clinical Endocrinology and Metabolism|May 21, 2010
Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart studySarah Rosner Preis, Joseph M Massaro, Udo Hoffmann, et al.
Archives of Neurology|November 15, 2006
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart StudyErnst J Schaefer, Vanina Bongard, Alexa S Beiser, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 11, 2006
Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart StudyDouglas S Lee, Jane C Evans, Sander J Robins, et al.
Vascular Medicine (London, England)|December 19, 2014
The relation of red blood cell fatty acids with vascular stiffness, cardiac structure and left ventricular function: the Framingham Heart StudyBernhard M Kaess, William S Harris, Sean Lacey, et al.
Obesity (Silver Spring, Md.)|March 27, 2010
Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart studySarah R Preis, Joseph M Massaro, Sander J Robins, et al.
Pageof 5